NAMPT and breast carcinoma: Certain breast cancers (especially ER−) depend on genomic amplification of PHGDH to divert glycolytic flux into serine and glycine metabolism [51,52] and PHGDH-high breast cancer lines are more susceptible to Nampt inhibition [3].